NDAOPHTHALMICSOLUTION
Approved
Sep 2023
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
RYZUMVI (phentolamine mesylate) by Septodont is soft-tissue anesthesia and the associated functional deficits is not fully understood. First approved in 2023.
Drug data last refreshed 6h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYZUMVI (phentolamine mesylate) is an ophthalmic solution that acts as an alpha-adrenergic antagonist to produce vasodilation in ocular tissues. The drug reverses the vasoconstrictive effects of local anesthetics containing epinephrine, restoring blood flow and reducing associated functional deficits. It represents a niche specialty solution for managing anesthetic complications in ophthalmologic procedures.
Growth13.1 years to LOE
Early-stage specialty ophthalmic product with no direct competitors, likely requiring focused regional sales and key opinion leader engagement.
Mechanism of Action
soft-tissue anesthesia and the associated functional deficits is not fully understood. Phentolamine mesylate, the active ingredient in OraVerse, produces an alpha-adrenergic block of relatively short duration resulting in vasodilatation when applied to vascular smooth muscle. In an animal model,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RYZUMVI offers niche career opportunities in a specialty ophthalmic market segment with zero competitive pressure and strong patent protection through 2039. Ideal for professionals seeking focused expertise in procedure-based ophthalmology rather than high-volume commercial environments.
Regional Sales Manager
Worked on RYZUMVI at Septodont? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.